search
Back to results

Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery (ProPS)

Primary Purpose

Probiotics, Infant, Newborn, Surgical Procedures, Operative

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
FloraBaby
Placebo
Sponsored by
University of Calgary
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Probiotics

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Infants born between 23 - 41 weeks of gestation
  2. Required gastrointestinal surgery (including spontaneous intestinal perforation, bowel atresia, mechanical bowel obstruction, volvulus, gastroschisis)
  3. Ready to start enteral feeding

Exclusion Criteria:

  1. Infants with major congenital anomalies excluding gastrointestinal tract
  2. Palliative care patients

4. Septic babies with positive blood, CSF or urine culture

Sites / Locations

  • University of CalgaryRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Probiotics

Placebo

Arm Description

subjects will be randomly assigned to receive FloraBaby

subjects will be randomly assigned to receive placebo

Outcomes

Primary Outcome Measures

Intestinal microbiome
Stool microbiome

Secondary Outcome Measures

Length of hospital stay
Time between birth and hospital discharge

Full Information

First Posted
August 24, 2017
Last Updated
November 4, 2022
Sponsor
University of Calgary
search

1. Study Identification

Unique Protocol Identification Number
NCT03266315
Brief Title
Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery
Acronym
ProPS
Official Title
Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 3, 2022 (Anticipated)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Congenital defects of the gastrointestinal tract commonly require surgical intervention in the neonatal period. Intestinal surgery during this critical period of microbiome acquisition results in aberrant colonization of the gastrointestinal tract by several pathways. Surgical stress is known to cause disruption of the gut barrier and increase intestinal permeability and bacterial translocation. This process triggers exaggerated immune responses that lead to inflammation and sometimes infectious complications. Post-operative use of antibiotics has been shown to potentiate the growth of pathogenic bacterial species Adults with abdominal surgery who received post-op probiotics reported a significant reduction in surgical site infection, urinary tract infection, and combined infection. Currently, probiotics used only in the non-surgical population of infants. The main objective of this study is to determine the impact of probiotics administration on the intestinal microbiome in neonates undergoing intestinal surgery.
Detailed Description
Research Objectives/Question: The main objective of this study is to determine the impact of probiotics administration on the intestinal microbiome in neonates undergoing gastrointestinal surgery. Primary question: Diversity and abundance of stool microbiome at after 1 and 3 weeks of initiation of probiotics Secondary outcomes: 1. Length of hospital stay Methodology: Study design This study will be a randomized controlled double-blinded trial in the NICU at Alberta Children's Hospital. Probiotics or placebo will be administered orally or via naso- or orogastric feeding tube. Intestinal microbiome data will be compared between the two groups. The study duration will be 24 months. Study Population Infants born between 23 - 41 weeks of gestation, admitted to NICU at Alberta Children's Hospital for gastrointestinal surgery. Inclusion Criteria: Infants born between 23 - 41 weeks of gestation Required gastrointestinal surgery in the first week of life (including spontaneous intestinal perforation, bowel atresia, mechanical bowel obstruction, volvulus, gastroschisis) Ready to start enteral feeding Exclusion Criteria: 1. Infants with major congenital anomalies excluding gastrointestinal tract 3. Palliative care patients 4. Septic babies with positive blood, CSF or urine culture Sample Size and feasibility: Connivant sample of 20 patients (10 in each group) Study protocol. Infants will be identified within 48 hours of surgery and parents will be approached for informed consent. Once consent is obtained, subjects will be randomly assigned to receive either probiotics or placebo. Investigators will conduct the randomization using a computer-generated table of random numbers generated at the University of Calgary. Preparation and Administration of Study Drug The study supplementation will be started at the when oral feeds will reach 24 mL/kg/day after surgery after collecting a stool/ostomy sample. The decision to start feeding will be made by the neonatal and surgical team. After the first stool/ostomy sample is obtained, one study sachet to a minimum of 1 mL of Expressed Breast Milk (EBM) (mothers own milk or donor human milk) once a day. Placebo sachet will be made of 0.3 g maltodextrin and be administered to the control group in the same manner. If the infant is placed NPO, the study drug will be stopped and restarted together with refeeding. Both probiotics and placebo will be packaged as a single-dose sachet. The study probiotic/placebo will be given till discharge. If the infant is transferred outside NICU, the study drug will be dispensed with the infant and clinical outcomes will be ascertained in collaboration with the local Pediatrician at the time of infants' discharge home. Sample collection Nurses will collect the stool samples at 3-time points: prior to initiation, 1 week after and 3 weeks after probiotic or placebo administration is commenced. "Stool" will be collected directly from the infant's ostomy bag and diaper with a sterile spatula. As soon as a sample is collected, the nurse will contact the investigators. The samples will then be placed in a laboratory freezer (-80°C) within 24 hours of collection. Batched samples will be transported to the University of Calgary Genomics laboratory for subsequent microbiome processing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Probiotics, Infant, Newborn, Surgical Procedures, Operative, Gastro-Intestinal Disorder

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Probiotics
Arm Type
Experimental
Arm Description
subjects will be randomly assigned to receive FloraBaby
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
subjects will be randomly assigned to receive placebo
Intervention Type
Biological
Intervention Name(s)
FloraBaby
Other Intervention Name(s)
Probiotics
Intervention Description
1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
Primary Outcome Measure Information:
Title
Intestinal microbiome
Description
Stool microbiome
Time Frame
3 weeks after surgury
Secondary Outcome Measure Information:
Title
Length of hospital stay
Description
Time between birth and hospital discharge
Time Frame
6 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infants born between 23 - 41 weeks of gestation Required gastrointestinal surgery (including spontaneous intestinal perforation, bowel atresia, mechanical bowel obstruction, volvulus, gastroschisis) Ready to start enteral feeding Exclusion Criteria: Infants with major congenital anomalies excluding gastrointestinal tract Palliative care patients 4. Septic babies with positive blood, CSF or urine culture
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Belal Alshaikh, MD, MSc
Phone
4039561588
Email
balshaik@ucalgary.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alixe Howlett, MD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Belal N Alshaikh, MD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Belal M ALshaikh, MD
Phone
4039561588
Email
balshaik@ucalgary.ca
First Name & Middle Initial & Last Name & Degree
Alixe M Howlett, MD
Email
alixe.howlett@ahs.ca
First Name & Middle Initial & Last Name & Degree
Belal M Alshaikh, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Probiotics Supplementation and Intestinal Microbiome in Neonates With Gastrointestinal Surgery

We'll reach out to this number within 24 hrs